Zafgen - IR Site News Releases http://ir.zafgen.com/ Zafgen - IR Site News Releases en Zafgen to Present at the JMP Securities Life Sciences Conference http://ir.zafgen.com/news-releases/news-release-details/zafgen-present-jmp-securities-life-sciences-conference-0 BOSTON , June 13, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield Thu, 13 Jun 2019 16:15:00 -0400 Zafgen - IR Site News Releases 9686 Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions http://ir.zafgen.com/news-releases/news-release-details/zafgen-presented-full-results-phase-2-clinical-trial-zgn-1061 Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced results for second cohort evaluating doses up to 1.8 mg Company also presented data demonstrating that treatment with ZGN-1061 improves measures of insulin sensitivity and beta-cell Mon, 10 Jun 2019 07:00:00 -0400 Zafgen - IR Site News Releases 9681 Zafgen Announces Regulatory Update on ZGN-1061 http://ir.zafgen.com/news-releases/news-release-details/zafgen-announces-regulatory-update-zgn-1061 Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly developed in vitro assays of human plasma coagulation and tissue factor expression qualitatively differentiate ZGN-1061 Company is working with FDA to translate in vitro data and confirm Thu, 30 May 2019 07:00:00 -0400 Zafgen - IR Site News Releases 9671 Zafgen Reports First Quarter 2019 Operating and Financial Results http://ir.zafgen.com/news-releases/news-release-details/zafgen-reports-first-quarter-2019-operating-and-financial Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061              Company is currently in the formal regulatory process related to the clinical hold for ZGN-1061; Update still anticipated in Q2 2019 PATH for PWS study continues enrollment with strong support Thu, 09 May 2019 16:15:00 -0400 Zafgen - IR Site News Releases 9651 Zafgen to Announce First Quarter 2019 Financial Results http://ir.zafgen.com/news-releases/news-release-details/zafgen-announce-first-quarter-2019-financial-results BOSTON , May 02, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will announce Thu, 02 May 2019 16:30:00 -0400 Zafgen - IR Site News Releases 9646 Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) http://ir.zafgen.com/news-releases/news-release-details/zafgen-inc-reports-inducement-grant-under-nasdaq-listing-rule BOSTON , April 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) (the “Company”) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced that on Thu, 04 Apr 2019 16:30:00 -0400 Zafgen - IR Site News Releases 9621 Zafgen to Present at the 31st Annual ROTH Conference http://ir.zafgen.com/news-releases/news-release-details/zafgen-present-31st-annual-roth-conference BOSTON , March 13, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield Wed, 13 Mar 2019 17:00:00 -0400 Zafgen - IR Site News Releases 9591 Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates http://ir.zafgen.com/news-releases/news-release-details/zafgen-reports-fourth-quarter-and-full-year-2018-operating-and Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Updates on progress preparing for FDA Type A meeting for ZGN-1061 Suspends IND filing plans for ZGN-1258 based on nonclinical finding in long-term toxicology studies Expanded executive team with highly Mon, 11 Mar 2019 12:05:00 -0400 Zafgen - IR Site News Releases 9576 Zafgen to Present at the Cowen and Company 39th Annual Health Care Conference http://ir.zafgen.com/news-releases/news-release-details/zafgen-present-cowen-and-company-39th-annual-health-care BOSTON , March 07, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield Thu, 07 Mar 2019 08:00:00 -0500 Zafgen - IR Site News Releases 9566 Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results http://ir.zafgen.com/news-releases/news-release-details/zafgen-host-conference-call-discuss-fourth-quarter-and-full-3 BOSTON , March 06, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a Wed, 06 Mar 2019 18:00:00 -0500 Zafgen - IR Site News Releases 9561